Personalized Exosome Therapies for Immune-Mediated Inflammatory Diseases

A next-generation exosome-based treatment platform for immune-mediated inflammatory diseases, integrating advanced genomics, nanotechnology, and real-time monitoring to provide personalized therapies with enhanced efficacy and safety.

The original patent's method of using mesenchymal stem cell-derived exosomes for treating immune-mediated inflammatory diseases has limitations, including lack of targeting specificity, variable efficacy, and limited understanding of exosome-mediated immune modulation. The new inventive concept addresses these limitations by introducing targeted delivery, personalized genomics, and real-time monitoring, enabling more effective and safe treatments.

The new inventive concept comprises a system for treating immune-mediated inflammatory diseases, featuring engineered exosomes that specifically target and modulate immune cells, and a nanocarrier for targeted delivery. Additionally, the concept includes a method for personalized treatment, involving genomic analysis to identify disease susceptibility markers and administration of tailored exosomes. A device for real-time monitoring of exosome-mediated immune modulation is also integrated, utilizing a biosensor and microfluidic chamber. Furthermore, the concept encompasses a composition featuring a synergistic combination of exosomes and small molecule inhibitors, as well as a method for generating a personalized exosome library using CRISPR-Cas9 gene editing.

The new claims introduce several non-obvious and novel features, including targeted delivery of exosomes using nanocarriers, personalized genomics-driven treatment, real-time monitoring of exosome-mediated immune modulation, and the use of CRISPR-Cas9 gene editing to generate disease-specific exosomes. These advancements provide a significant improvement over the original patent, enabling more effective and safe treatments for immune-mediated inflammatory diseases.

Alternative embodiments of the inventive concept could include the use of different types of stem cells or exosome sources, varying nanocarrier designs, and integration with other therapeutic modalities, such as gene therapy or immunotherapy. Additionally, the concept could be adapted for treating other diseases or conditions, such as cancer or neurodegenerative disorders.

The new inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of personalized medicine and immunotherapy. The market for exosome-based therapies is expected to grow rapidly, driven by increasing demand for more effective and targeted treatments for immune-mediated inflammatory diseases.